Zacks Investment Research·2d ago
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
Boston Scientific is executing a sustained high-growth strategy, with revenue expanding from $3.9B in 2024Q1 to $5.4B in 2026Q2, driven by a combination of organic momentum and aggressive M&A, as evidenced by a $4.2B increase in goodwill over the period. The c...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has decelerated to 7.5% year-over-year in 2026Q2, while gross margin exhibits volatility, peaking at 74.5% in 2025Q4 before retreating to 70.7%, suggesting potential product mix or cost fluctuations.
Boston Scientific Corporation is recognized for its leadership in minimally invasive medical devices, driving innovation in the healthcare sector.
Vanguard Group holds a significant 9.8% stake in Boston Scientific Corporation, indicating strong institutional confidence in the company.
With trailing and forward P/E ratios of 50.06 and 26.95 respectively, Boston Scientific Corporation presents compelling valuation opportunities for investors.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.86+3.0% vs $0.83 | $5.4B+1.2% vs $5.4B |
Q2 2026 Apr 22, 2026 | $0.80+1.5% vs $0.79 | $5.2B+0.6% vs $5.2B |
Q1 2026 Feb 4, 2026 | $0.80+2.4% vs $0.78 | $5.3B+0.1% vs $5.3B |
Q4 2025 Oct 22, 2025 | $0.75+5.0% vs $0.71 | $5.1B+1.9% vs $5.0B |
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
Corient Private Wealth LP increased its stake in shares of Boston Scientific Corporation (NYSE: BSX) by 25.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 233,728 shares of the medical equipment provider's stock after acquiring an additional 47,125 shares during
Benchmark BSX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Boston Scientific Corporation (BSX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $44.92 | $66.77B | 23.15 | 19.87% | 14.38% | 12.42% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $88.78 | $51.12B | 48.51 | 11.55% | 15.43% | 9.66% | — | |
| $275.07 | $105.45B | 32.75 | 11.16% | 14.43% | 16.36% | — | |
| $93.98 | $18.18B | 26.47 | 7.2% | 9.48% | 6.36% | — | |
| $183.00 | $50.42B | 31.39 | 8.23% | 4.52% | 3.79% | — |
Boston Scientific Corporation (BSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Boston Scientific Corporation (BSX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 26, 2026·SEC
Jul 29, 2026·SEC
Jul 27, 2026·SEC
Get notified when BSX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Boston Scientific Corporation (BSX) stock FAQ — growth, dividends, profitability & financials explained
Boston Scientific Corporation (BSX) reported $21.00B in revenue for fiscal year 2025. This represents a 1336% increase from $1.46B in 1996.
Boston Scientific Corporation (BSX) grew revenue by 19.9% over the past year. This is strong growth.
Yes, Boston Scientific Corporation (BSX) is profitable, generating $3.67B in net income for fiscal year 2025 (14.4% net margin).
Boston Scientific Corporation (BSX) has a return on equity (ROE) of 12.4%. This is reasonable for most industries.
Boston Scientific Corporation (BSX) generated $3.63B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
